Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Dec 14;7:17600. doi: 10.1038/s41598-017-17928-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Antibody blockade of SCARF-1 on HSEC inhibits the adherence of CD4⁺ T lymphocytes in the presence of TNFα and LPS. (a,b and c; left panels) Representative images of CD4⁺ T cells adhered to HSEC stimulated with (a) TNFα (10 ng/ml), (b) LPS (1 µg/ml) or (c) TNFα and LPS together. HSEC were pre-treated with isotype matched controls (IMC; 10 µg/ml), SCARF-1 blocking antibody (10 µg/ml), VCAM-1 blocking antibody (10 µg/ml) or SCARF-1 and VCAM-1 in combination (both 10 µg/ml). Black arrowheads highlight adherent CD4⁺ T lymphocytes on the HSEC monolayer. (a,b and c; right panels) Quantification of adherent CD4⁺ T cells in the presence of the blocking antibodies, with the percentage inhibition indicated. *, **, *** and **** all indicate statistical significance where p ≤ 0.05, p ≤ 0.01, p ≤ 0.005 and p ≤ 0.001, respectively. ns = not significant. n = 3 independent experiments with different lymphocyte and HSEC donors, with 12 fields of view taken from each.